Biomarkers of Atrial Fibrillation Complicated With Stroke Based on Proteomics and Metabolomics

Stroke Clinical Trial

Official title:

Biomarkers of Atrial Fibrillation Complicated With Stroke Based on Proteomics and Metabolomics

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05181787
• Other study ID #: AF and stroke 1
• Status: Recruiting
• Start date: December 20, 2021
• Est. completion date: December 31, 2023

Study information

• Verified date: January 2022
• Source: First Affiliated Hospital of Harbin Medical University
• Contact: Haiyu Zhang, MD
• Phone: 86-451-85555009
• Email: zhanghaiyu819[@]163.com
• Is FDA regulated: No
• Study type: Observational [Patient Registry]

Clinical Trial Summary

Thrombus shedding in patients with atrial fibrillation (AF) can lead to cerebral artery embolism. Stroke caused by AF is very dangerous, which not only threatens the life of patients, but also seriously affects the quality of life. This study aims to explore the biomarkers of stroke in patients with AF by integrating proteomics and metabolomics data, and establish the network relationship of stroke in patients with AF, so as to reveal the molecular mechanism of stroke in patients with AF.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 200
• Est. completion date: December 31, 2023
• Est. primary completion date: December 31, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Age 18 years or above

2. Admission with atrial fibrillation or clinic visit for atrial fibrillation

3. Receive routine anticoagulant therapy;

4. Signing the consent form

Exclusion Criteria:

1. Pregnant women;

2. Lactating women;

3. Severe mitral stenosis;

4. Severe impairment of liver function;

5. Severe renal insufficiency;

6. Thyroid dysfunction requiring treatment.

Related Conditions & MeSH terms

• Atrial Fibrillation
• Stroke

Intervention

Diagnostic Test:
• Proteomics
Proteomic data were obtained by LC-MS/MS Analysis-DIA platform.
• Metabolomics
Metabolomic data were obtained by UPLC-QTOF/MS platform.

Locations

Country	Name	City	State
China	Yan	Harbin	Heilongjiang

Sponsors (1)

Lead Sponsor	Collaborator
Yue LI

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Biomarkers of atrial fibrillation complicated with stroke based on proteomics and metabolomics	By combining proteomics and metabolomics data, the investigators were able to identify the common pathways involved in AF with stroke.	1 day
Secondary	Quantitative changes of individual metabolites and proteins were calculated and graphed using the KEGG mapping tools.		1 day
Secondary	By combining proteomics and metabolomics data, the investigators were able to identify the common pathways involved in AF with stroke.		1 day
Secondary	All of the omics data were used to compare proteins/enzymes with metabolic pathways.		1 day